The Cooper Companies, Inc

Eyebright Medical and CooperVision signed a strategic cooperation agreement in Xiamen on August 3, under which the two parties will establish a pathway combining direct brand supply with instant retail operations, driving the standardization and digital development of the contact lens industry. CooperVision awarded brand authorization plaques to Eyebright Medical subsidiaries Meiyuetong and Tongkuaigou. Going forward, they will focus on three major goals—multiple products, broad coverage, and expanded astigmatism offerings—leveraging CooperVision's full-cycle eye health product line and Eyebright Medical's instant retail network to connect online and offline service links and jointly empower thousands of offline stores to list products. CooperVision's Asia-Pacific Sales Vice President James Mounter stated that this collaboration aims to promote the professional upgrade of instant retail for contact lenses, striving for leapfrog growth from 2026 to 2027. Dr. Xie Jiangbing, Chairman of Eyebright Medical, said that the company will rely on the nationwide instant retail warehouse-store network and 24-hour smart stores built under its TOPPOP contact lens instant retail channel brand to export digital channel operation capabilities and help traditional stores transform.

Zacks Investment Research maintains a Hold rating on Cooper Companies, citing growth in premium contact lenses and operational restructuring, while near-term headwinds persist. CooperVision's premium lens migration and MiSight myopia-management leadership are driving performance, with MyDay daily silicone hydrogel lenses achieving double-digit growth and MiSight growing 23%. The company posted a 20% increase in adjusted earnings per share as operating expenses declined, reflecting durable operating leverage from last year's restructuring. However, challenges include weakness in Japan's Asia-Pacific segment, competitive pressure on legacy hydrogel products, and ongoing uncertainty in CooperSurgical's fertility business, particularly in China and the Middle East. Shares have lost 13.8% year-to-date, underperforming the industry's 2% decline and the S&P 500's 10.3% rise.

Oakmark Global Fund initiated a new position in The Cooper Companies during the second quarter of 2026, citing an attractive entry point after the stock pulled back alongside the broader medical technology sector. The fund noted Cooper's contact lens business benefits from an oligopolistic market structure, high barriers to entry, and recurring revenue, and highlighted the company's track record of market share gains in specialty lenses and its private-label strategy. The stock closed at $68.51 on July 14, 2026, with a market capitalization of $13.36 billion, and the fund believes it trades at a meaningful discount to peers, private market transactions, and its own history.

CooperCompanies released its 2025 Corporate Sustainability Report, disclosing Scope 3 greenhouse gas emissions for the first time. The report highlights expanded performance metrics and progress on sustainability priorities, including the launch of CooperVision's MADE BETTER platform for responsible sourcing and waste reduction, and CooperSurgical's ViaBL Super-Fast Blastocyst Warming Kit and a renewable cooler made from 85% plant-based fibers for IVF shipments. The company also aligned with the Task Force on Climate-related Financial Disclosures for the first time, while continuing adherence to SASB Standards. President and CEO Al White credited the global team's partnership and innovation for these achievements.

Stifel reiterated a Buy rating on Cooper Companies with an $85 price target as the company advances talks to sell its CooperSurgical unit. Multiple parties are interested in the business, and all related legal issues have been settled. Stifel estimates that after the divestiture, Cooper stock could be worth $80 per share, implying roughly 21% upside. CEO Albert White said the vast majority of sale proceeds would fund share repurchases. Cooper Companies operates CooperVision for contact lenses and CooperSurgical for women's health products.